Skip to main content
    G

    Gossamer Bio Inc (GOSS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.98
    +0.01 (+0.09%)

    Market Cap: $67.10M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Gossamer Bio Inc (GOSS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Gossamer Bio (GOSS) to earn -$18.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $40.51M. Of 8 analysts, 4 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.63, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.

    RatingAnalystsShare
    Strong Buy112.5%
    Buy337.5%
    Hold337.5%
    Sell00.0%
    Strong Sell112.5%
    Consensus
    Hold
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 58.7%.

    Fiscal year ending Dec 31, 2026
    -$18.01
    EPS consensus, revenue $40.51M
    Fiscal year ending Dec 31, 2027
    -$15.61
    EPS consensus, revenue $16.73M
    Next report
    Mar 15, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$18.01-$23.08 to -$11.204$40.51M$26.19M to $68.40M7
    Dec 31, 2027-$15.61-$28.80 to -$2.885$16.73MN/A7

    Quarterly Estimates

    The EPS consensus falls from -$3.23 for the quarter ending Dec 31, 2026 to -$6.39 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.23-$6.13 to -$1.609$3.59MN/A9
    Mar 31, 2027-$6.39-$7.20 to -$5.603$840000N/A5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$34.08.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$18.01-$16.32-$14.40-$31.91-$34.08N/A
    Fiscal year ending Dec 31, 2027-$15.61-$15.62-$14.48-$7.38-$7.73N/A
    Quarter ending Mar 31, 2027-$6.39-$6.40-$5.60-$5.07-$5.07N/A

    Frequently Asked Questions About GOSS

    What is the GOSS stock forecast?

    Consensus analyst estimates put Gossamer Bio's EPS at -$18.01 for the fiscal year ending Dec 31, 2026, on revenue of $40.51M. The consensus rating from 8 analysts is Hold.

    How do analysts rate GOSS stock?

    Of 8 analysts covering Gossamer Bio, 1 rates it Strong Buy, 3 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from GOSS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$18.01, with estimates from -$23.08 to -$11.20 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$15.61, with estimates from -$28.80 to -$2.88 from 5 analysts.

    What revenue do analysts expect from Gossamer Bio next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $40.51M, with estimates from $26.19M to $68.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $16.73M.

    How many analysts cover GOSS?

    8 analysts rate Gossamer Bio stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.